Publications en collaboration avec des chercheurs de Hospital Universitario La Fe (18)

2024

  1. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

    British Journal of Haematology, Vol. 205, Núm. 2, pp. 503-509

  2. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

    Blood, Vol. 144, Núm. 16, pp. 1722-1731

  3. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

    British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535

  4. WHO/ICC Classification for Myelodysplastic Neoplasms/Syndromes Performs Better for Subtype Cytomorphological Diagnosis?

    Diagnostics, Vol. 14, Núm. 15

2023

  1. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study

    Cancer Medicine, Vol. 12, Núm. 6, pp. 6536-6546

  2. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

    HemaSphere, Vol. 7, Núm. 10, pp. E961

  3. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

    Cell Reports Medicine, Vol. 4, Núm. 12

2021

  1. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

    The Lancet Haematology, Vol. 8, Núm. 2, pp. e135-e148

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

2018

  1. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

    Haematologica

2017

  1. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma

    Cancer Medicine, Vol. 6, Núm. 11, pp. 2507-2514

  2. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

2016

  1. Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes

    Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292

  2. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes

    Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551

2015

  1. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

    Blood Cancer Journal, Vol. 5

  2. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients

    American Journal of Hematology, Vol. 90, Núm. 8, pp. 686-690

2013

  1. Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations

    British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86

2012

  1. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

    Haematologica, Vol. 97, Núm. 7, pp. 1036-1041